State-level Medicaid coverage indicates whether an individual state includes obesity-indicated GLP-1s (Saxenda, Wegovy, and Zepbound) or Type 2 diabetes-indicated GLP-1s (Ozempic, Mounjaro, and Rybelsus) on its formulary or preferred drug list, including non-preferred or restricted coverage
Medical factors contributing to plateaus include suboptimal dosing, weight-promoting concurrent medications, underlying endocrine disorders, and medication non-adherence
In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration)
In studies, after 52 weeks, participants on the highest dose of Mounjaro (15 mg per week): Lowered their total cholesterol by about 5.6 percent Lowered their triglycerides by 22.5 percent Lowered their LDL (bad) cholesterol by 7.9 percent Lowered their VLDL cholesterol by 21.8 percent Increased their HDL (good) cholesterol by 10.8 percent Additionally, a meta-analysis (analysis of data from several clinical trials) from The Lancet found that Ozempic lowered cardiovascular risk and even decreased the risk of death in people with diabetes and heart disease
Because it affects three signaling pathways simultaneously, it enables investigation of receptor cross-talk and synergistic mechanisms that were difficult to study with single or dual-target compounds
These molecules are harmful because, if left unchecked, they can lead to damage of important cellular components such as DNA and mitochondria (the energy producing parts of a cell)